Skip to Content

Label Changes for:

Parlodel SnapTabs (bromocriptine mesylate) Tablets and Capsules

January 2012

Changes have been made to the PRECAUTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – January 2012



Parkinson’s Disease
  • Postmarketing reports suggest that patients treated with anti-Parkinson medications can experience intense urges to gamble, increased....
  • Epidemiological studies have shown that patients with Parkinson’s disease have a higher risk (2-approximately 6-fold higher) of developing melanoma than the general population. Whether the increased risk observed was.....
Information for Patients
  • Patients and their caregivers should be alerted to the possibility that they may experience intense urges.....